Wall Street brokerages forecast that Recro Pharma Inc (NASDAQ:REPH) will post $16.01 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Recro Pharma’s earnings, with estimates ranging from $15.65 million to $16.49 million. Recro Pharma posted sales of $19.04 million in the same quarter last year, which would indicate a negative year over year growth rate of 15.9%. The company is scheduled to report its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Recro Pharma will report full year sales of $75.42 million for the current year, with estimates ranging from $75.00 million to $76.05 million. For the next year, analysts expect that the firm will report sales of $89.15 million, with estimates ranging from $76.90 million to $105.00 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Recro Pharma.
Several brokerages have commented on REPH. Zacks Investment Research downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. ValuEngine downgraded Recro Pharma from a “buy” rating to a “hold” rating in a research report on Monday, December 3rd. Janney Montgomery Scott restated a “buy” rating and issued a $13.00 target price on shares of Recro Pharma in a research report on Thursday, January 31st. Oppenheimer set a $18.00 target price on Recro Pharma and gave the company a “buy” rating in a report on Thursday, November 8th. Finally, Piper Jaffray Companies set a $10.00 price target on Recro Pharma and gave the company a “buy” rating in a report on Thursday, November 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $13.04.
NASDAQ REPH opened at $8.55 on Thursday. Recro Pharma has a 12-month low of $4.78 and a 12-month high of $13.05. The company has a market cap of $186.85 million, a price-to-earnings ratio of -4.30 and a beta of -0.31. The company has a debt-to-equity ratio of 4.04, a quick ratio of 1.16 and a current ratio of 1.36.
Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its holdings in Recro Pharma by 26.0% during the 3rd quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock worth $3,416,000 after purchasing an additional 99,200 shares during the period. Virtu Financial LLC bought a new stake in Recro Pharma in the 3rd quarter valued at $156,000. BlackRock Inc. grew its position in shares of Recro Pharma by 27.6% during the 2nd quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock worth $5,747,000 after purchasing an additional 247,559 shares in the last quarter. Northern Trust Corp grew its holdings in Recro Pharma by 28.0% in the second quarter. Northern Trust Corp now owns 220,965 shares of the specialty pharmaceutical company’s stock worth $1,109,000 after purchasing an additional 48,297 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of Recro Pharma by 29.5% in the third quarter. Acadian Asset Management LLC now owns 290,124 shares of the specialty pharmaceutical company’s stock worth $2,063,000 after purchasing an additional 66,062 shares in the last quarter. Institutional investors and hedge funds own 52.11% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.